F
Frans Van de Werf
Researcher at Katholieke Universiteit Leuven
Publications - 8
Citations - 1644
Frans Van de Werf is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Streptokinase & Randomized controlled trial. The author has an hindex of 5, co-authored 8 publications receiving 1625 citations. Previous affiliations of Frans Van de Werf include University of Massachusetts Medical School.
Papers
More filters
Journal ArticleDOI
Predictors of 30-Day Mortality in the Era of Reperfusion for Acute Myocardial Infarction Results From an International Trial of 41 021 Patients
Kerry L. Lee,Lynn H. Woodlief,Eric J. Topol,W. Douglas Weaver,Amadeo Betriu,Jacques Col,Maarten L. Simoons,Phil Aylward,Frans Van de Werf,Robert M. Califf +9 more
TL;DR: In this article, the authors performed a comprehensive analysis of relations between baseline clinical data and 30-day mortality and developed a multivariable statistical model for risk assessment in candidates for thrombolytic therapy.
Journal ArticleDOI
Stroke After Thrombolysis Mortality and Functional Outcomes in the GUSTO-I Trial
Joel M. Gore,Christopher B. Granger,Maarten L. Simoons,Michael A. Sloan,W. Douglas Weaver,Harvey D. White,Gabriel I. Barbash,Frans Van de Werf,Philip E. Aylward,Eric J. Topol,Robert M. Califf +10 more
TL;DR: In this paper, the authors analyzed the incidence, timing, and outcomes of stroke in an international trial and found that 1.4% of the patients had a stroke (93% anatomic documentation) and the risk ranged from 1.19% with streptokinase/subcutaneous heparin therapy to 1.64% with combination thrombolytic therapy.
Journal ArticleDOI
Variations in Patient Management and Outcomes for Acute Myocardial Infarction in the United States and Other Countries: Results From the GUSTO Trial
Frans Van de Werf,Eric J. Topol,Kerry L. Lee,Lynn H. Woodlief,Christopher B. Granger,Paul W. Armstrong,Gabriel I. Barbash,John R. Hampton,Alan D. Guerci,R. John Simes,Allan M. Ross,Robert M. Califf +11 more
TL;DR: No significant evidence for a differentially greater benefit of accelerated rt-PA over streptokinase was found in US vs non-US patients, however, increased procedure and treatment use in the United States was associated with only a small decrease in short-term mortality.
Journal ArticleDOI
Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion
Eric J. Topol,Paul W. Armstrong,Frans Van de Werf,Neal S. Kleiman,Kerry L. Lee,Douglas C. Morris,Maarten L. Simoons,Gabriel I. Barbash,Harvey D. White,Robert M. Califf +9 more
TL;DR: The GUSTO trial is a large scale international trial of new myocardial reperfusion strategies and a strategy was developed to provide assurance of patient safety during large scale investigational use of an aggressive thrombolytic regimen to facilitate the design of future large scale randomized trials in cardiovascular medicine.